Biopharma Due Diligence

December 10, 2019 Leah Hoffmann

A global biopharma company was evaluating an acquisition whose potential indications ranged from gastrointestinal disorders to ophthalmology. With a key leader out on vacation and the deadline for a non-binding term sheet drawing near, the company’s head of Commercial Business Development turned to Business Talent Group.

In the span of a few days, we delivered a two-person team to help the company extend and finalize its commercial evaluation. A biotech investment specialist customized a model that looked at multiple scenarios and helped size patient populations across different indications. An analyst assessed market access and competitive dynamics. A week later, the team had the figures it needed to make a successful bid; they are now proceeding to the next phase of the acquisition.

About the Author

Leah Hoffmann

Leah Hoffmann is a former journalist who has worked for Forbes.com and The Economist. She is passionate about clear thinking, sharp writing, and strong points of view.

More Content by Leah Hoffmann
Previous Article
Strategic Workforce Planning: Behind the Buzzword
Strategic Workforce Planning: Behind the Buzzword

Strategic workforce planning has emerged as a critical way for HR and business leaders to deliver on broade...

Next Article
Executive Roundtable: The CEO View on Strategic Workforce Planning
Executive Roundtable: The CEO View on Strategic Workforce Planning

SHRM People + Strategy Journal sits down with BTG Co-CEO Jody Miller to discuss the role of HR, CEOs, and t...

Get our free guide to working with on-demand talent.

Read Now